Dyspnoea after antiplatelet agents: The AZD6140 controversy

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 529-533

  Serebruany, V L ^a   Stebbing, J ^b   Atar, D ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

3 [7 [2 (3,4 DIFLUOROPHENYL)CYCLOPROPYLAMINO] 5 PROPYLTHIO 1,2,3 TRIAZOLO[4,5 D]PYRIMIDIN 3 YL] 5 HYDROXYMETHOXY 1,2 CYCLOPENTANEDIOL; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ADENOSINE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; PRASUGREL; THROMBOCYTE RECEPTOR; TICLOPIDINE; TIROFIBAN;

ALGORITHM; ANGINA PECTORIS; ARACHIDONIC ACID METABOLISM; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FLUID RETENTION; HEART INFARCTION; HUMAN; HYPOTENSION; IMMUNE SYSTEM; LOW DRUG DOSE; LUNG FUNCTION TEST; MICROTHROMBUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADENOSINE; DYSPNEA; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 33847050871     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01294.x     Document Type: Article

References (35)

1. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27: 1038-47 (Epub ahead of print).
2. Quan D, LoVecchio F, Clark B, Gallagher JV III. Prehospital use of aspirin rarely is associated with adverse events. Prehospital Disaster Med 2004; 19: 362-5.
3. Quinn MW, Dillard TA. Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent. Chest 1999; 116: 257-60.
4. Miyaoka Y, Urano Y, Nameda Y et al. Abstract a case of dermatomyositis complicated by thrombotic thrombocytopenic purpura. Dermatology 1997; 194: 68-71.
5. Davutoglu V, Soydinc S, Sezen Y. Complete lysis of left ventricular giant thrombus with fibrinolytic therapy in clopidogrel resistant patient. J Thromb Thrombolysis 2003; 15: 59-63.
6. Suzuki K, Tachibana A, Hatakeyama S, Okano H. A case of cilostazol-induced pneumonitis. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 156-9.
7. Gutersohn A, Zimmermann U, Bartel T, Erbel R. A rare case of acute 'infective' myocardial infarction triggered by acute parvovirus B19 myocarditis. Nat Clin Pract Cardiovasc Med 2005; 2: 167-71.
8. Coons JC, Barcelona RA, Freedy T, Hagerty MF. Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 2005; 39: 368-72.
9. Roman MR, Angelides S, Freeman AP, Parker MK, da Silva I. The safety of dipyridamole in patients undergoing myocardial perfusion scintigraphy prior to lung volume reduction surgery. Eur J Nucl Med 2001; 28: 1405-8.
10. Shaffer J, Simbartl L, Render ML et al. Patients with stable chronic obstructive pulmonary disease can safely undergo intravenous dipyridamole thallium-201 imaging. Am Heart J 1998; 136: 307-13.
11. Matias-Guiu J, Ferro JM, Alvarez-Sabin J et al.; TACIP Investigators. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34: 840-8.
12. Scrutinio D, Cimminiello C, Marubini E, Pitzalis MV, Di Biase M, Rizzon P. Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. J Am Coll Cardiol 2001; 37: 1259-65.
13. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
14. Wiviott SD, Antman EM, Winters KJ et al.; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111: 3366-73.
15. Mueller C, Laule-Kilian K, Frana B et al. Use of B-type natriuretic peptide in the management of acute dyspnea in patients with pulmonary disease. Am Heart J 2006; 151: 471-7.
16. Brieger D, Eagle KA, Goodman SG et al.; GRACE Investigators. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004; 126: 461-9.
17. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-1998. A 49-year-old woman with thrombotic thrombocytopenic purpura and severe dyspnea during plasmapheresis and transfusion. N Engl J Med 1998; 339: 2005-12.
18. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993; 2: 1060-1.
19. Griffiths C, Fisher M. Abciximab-induced thrombocytopenia. QJM 2002; 95: 635-6.
20. Zakarija A, Bandarenko N, Pandey DK et al. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke 2004; 35: 533-7.
21. Chang JC, Aly ES. Acute respiratory distress syndrome as a major clinical manifestation of thrombotic thrombocytopenic purpura. Am J Med Sci 2001; 321: 124-8.
22. Szmidt M, Wasiak W. The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma. J Investig Allergol Clin Immunol 1996; 6: 121-5.
23. Jawien J. A new insight into aspirin-induced asthma. Eur J Clin Invest 2002; 32: 134-8.
24. Semple PF. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J Hypertens Suppl 1995; 13: S17-21.
25. Scott AC, Wensel R, Davos CH et al. Putative contribution of prostaglandin and bradykinin to muscle reflex hyperactivity in patients on Ace-inhibitor therapy for chronic heart failure. Eur Heart J 2004; 20: 1806-13.
26. Xiao Z, Theroux P, Frojmovic M. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thromb Haemost 1999; 81: 281-5.
27. Lev EI, Patel RT, Maresh KJ et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47: 27-33.
28. Cannon CP, Husted S, Storey RF et al. The DISPERSE2 trial: safety, tolerability, and preliminary efficacy of AZD6140, the first oral reversible ADP receptor antagonist, compared with clopidogrel in patients with non ST-elevation acute coronary syndrome. AHA 2005; American Heart Association (AHA), Dallas, 15 November 2005. Poster #C228.
29. Serebruany VL, Malinin AI, O'Connor CM, Gurbel PA. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy). Am Heart J 2003; 146: 91-8.
30. Basoglu OK, Pelleg A, Essilfie-Quaye S, Brindicci C, Barnes PJ, Kharitonov SA. Effects of aerosolized adenosine 5′-triphosphate vs adenosine 5′-monophosphate on dyspnea and airway caliber in healthy nonsmokers and patients with asthma. Chest 2005; 128: 1905-9.
31. Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA. Phase II study of intravenous adenosine 5′-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer. Invest New Drugs 1998; 16: 81-5.
32. Udelson JE, Heller GV, Wackers FJ et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 2004; 109: 457-64.
33. Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J 2006; 151: e1-10.
34. Serebruany V. Dyspnea after AZD6140: safety first? Eur Heart J 2006; 12: 1505.
35. Husted S. Dyspnea after AZD6140: safety first?: reply. Eur Heart J 2006; 12: 1506.